Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor
| Autor: | Jason Hsu, Hannah Garrigan, Turner D Wibbelsman, Allen C. Ho, Anthony Obeid, Phoebe L Mellen, Rebecca R. Soares, Durga S. Borkar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Visual acuity genetic structures Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors Ranibizumab Age related Ophthalmology medicine Humans Macula Lutea Intravitreal bevacizumab Lost to follow-up Retrospective Studies Aflibercept Aged 80 and over Anti vegf business.industry Macular degeneration medicine.disease eye diseases Bevacizumab Cross-Sectional Studies Receptors Vascular Endothelial Growth Factor Treatment Outcome Intravitreal Injections Wet Macular Degeneration Female Lost to Follow-Up sense organs medicine.symptom business Tomography Optical Coherence Follow-Up Studies medicine.drug |
| Zdroj: | Ophthalmology Retina. 4:134-140 |
| ISSN: | 2468-6530 |
| DOI: | 10.1016/j.oret.2019.07.010 |
| Popis: | To determine outcomes of eyes with neovascular age-related macular degeneration (nAMD) receiving intravitreal anti-vascular endothelial growth factor (VEGF) injections who return after a period of being lost to follow-up (LTFU).Retrospective, cross-sectional study.Eyes that received intravitreal bevacizumab, ranibizumab, or aflibercept for nAMD and were LTFU for6 months.Comparison of visual outcomes and structural parameters at the visit before LTFU, return visit, and final visit.Logarithm of the minimum angle of resolution (logMAR) visual acuity (VA), presence of subretinal fluid and intraretinal fluid, and central foveal thickness (CFT) by OCT.A total of 93 eyes of 77 patients were included in the analysis. Mean duration from date of LTFU to return was 346 (±122) days. Overall, 53.7% of patients had worse median logMAR VA by the final visit. Median logMAR VA worsened from 0.60 (0.40-2.00) (Snellen 20/80 [20/50-20/2000]) at the visit before LTFU to 1.00 (0.48-2.00) (20/200 [20/60-20/2000]) at the return visit (P0.001). Median logMAR VA remained worse at 6- and 12-months after return from LTFU: 1.00 (0.48-2.00) (20/200 [20/60-20/2000]) (P = 0.001) and 0.70 (0.44-1.30) (20/100 [20/55-20/399]) (P = 0.004), respectively. Despite a mean of 383 (±270) days of follow-up after returning and 5.0 (±5.1) additional injections, the median logMAR VA remained worse at 1.00 (0.54-2.00) (20/200 [20/70-20/2000]) at the final visit compared with the visit before LTFU (P0.001). There was greater worsening in mean logMAR VA from the visit before LTFU to the final visit in eyes that received bevacizumab (0.32) and ranibizumab (0.28) compared with aflibercept (P = 0.003, P = 0.04, and P = 0.03, respectively). Mean CFT increased from 201 (±106) μm at the visit before LTFU to 240 (±147) μm at return (P = 0.004). By the final visit, the mean CFT had decreased to 183 (±101) μm, which was not significantly different from the visit before LTFU (P = 0.10).Eyes with nAMD receiving intravitreal anti-VEGF that were LTFU experience significant VA decline at the return visit that persists on final follow-up despite normalization of CFT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|